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Introduction: Real-time monitoring of biologic changes in tumors may be possible by investigating the transitional
cells such as circulating tumor cells (CTCs) and disseminated tumor cells in bone marrow (BM-DTCs). However, the
small numbers of CTCs and the limited access to bone marrow aspirates in cancer patients pose major hurdles. The
goal of this study was to determine whether breast cancer (BC) patient-derived xenograft (PDX) mice could provide
a constant and renewable source of CTCs and BM-DTCs, thereby representing a unique system for the study of
metastatic processes.
Methods: CTCs and BM-DTCs, isolated from BC PDX-bearing mice, were identified by immunostaining for human
pan-cytokeratin and nuclear counterstaining of red blood cell-lysed blood and bone marrow fractions, respectively.
The rate of lung metastases (LM) was previously reported in these lines. Associations between the presence of CTCs,
BM-DTCs, and LM were assessed by the Fisher’s Exact and Cochran-Mantel-Haenszel tests. Two separate genetic
signatures associated with the presence of CTC clusters and with lung metastatic potential were computed by
using the expression arrays of primary tumors from different PDX lines and subsequently overlapped to identify
common genes.
Results: In total, 18 BC PDX lines were evaluated. CTCs and BM-DTCs, present as either single cells or clusters,
were detected in 83% (15 of 18) and 62.5% (10 to16) of the lines, respectively. A positive association was noted
between the presence of CTCs and BM-DTCs within the same mice. LM was previously found in 9 of 18 (50%)
lines, of which all nine had detectable CTCs. The presence of LM was strongly associated with the detection of
CTC clusters but not with individual cells or detection of BM-DTCs. Overlapping of the two genetic signatures
of the primary PDX tumors associated with the presence of CTC clusters and with lung metastatic potential
identified four genes (HLA-DP1A, GJA1, PEG3, and XIST). This four-gene profile predicted distant metastases-free
survival in publicly available datasets of early BC patients.
Conclusion: This study suggests that CTCs and BM-DTCs detected in BC PDX-bearing mice may represent a
valuable and unique preclinical model for investigating the role of these rare cells in tumor metastases.* Correspondence: rschiff@bcm.edu; mtrivedi@UH.EDU
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Circulating tumor cells (CTCs) are cancer cells originat-
ing from either a primary or metastatic tumor and circu-
lating freely in the peripheral blood [1]. It has been
proposed that the spread of a primary tumor through
the bloodstream as CTCs is a critical step in tumor me-
tastasis [2,3]. In breast cancer (BC), CTCs can be de-
tected in patients at early stages or late stages of disease
with overt metastases [4-6]. Many studies have shown
that the detection of CTCs may help to predict the out-
come in patients with different types of cancers. In
particular, the enumeration of CTCs before starting sys-
temic treatment is associated with clinical outcome in
both metastatic and non-metastatic BC patients [4,6,7].
Furthermore, CTC count evaluated at different time
points during systemic treatment is a reliable surrogate
marker of treatment response [8-12]. Preliminary studies
have suggested that selecting therapies based on molecu-
lar characteristics of CTCs may improve treatment out-
comes in patients [13-15]. Because CTCs are found in
circulation as a collectable fraction that is representative
of the tumor, they may provide an ideal model to study
the biology of the tumor at various intervals before and
during treatment [16].
Interestingly, the presence of CTCs has been found to
correlate with the presence of disseminated tumor cells
in the bone marrow (BM-DTCs) in BC patients [17,18].
Similar to CTCs, BM-DTCs play a crucial role in the
metastatic cascade as the earliest detectable form of
micrometastatic disease and potential precursors of overt
metastases [19]. Notably, several studies have shown that
persistence of BM-DTCs after therapy predicts a higher
risk of relapse in BC patients [20,21]. Therefore, BM-DTCs
represent an additional tool for studying the metastatic
process in its initial stage.
Despite the evidence to support the roles of CTCs and
BM-DTCs in studying tumor biology and predicting
treatment response, routine clinical and preclinical use
of these cells is challenging because of multiple factors.
First, CTCs are present in small numbers in only 10% to
50% of BC patients [22-24]. Therefore, they cannot be
isolated in sufficient numbers from a small volume of
blood from most patients. Similarly, a longitudinal study
of BM-DTCs is impractical because of limited access to
bone marrow aspirates and the small number of DTCs
that can be enriched from aspirates of standard volume.
In addition, commonly used methods to detect CTCs
use antibodies against epithelial cell markers and exclude
identification of tumor cells with mesenchymal proper-
ties. This is especially problematic, as the cells that have
undergone epithelial-to-mesenchymal transition (EMT)
may play an essential role in the metastatic process [25].
To address these major challenges, we aimed to deter-
mine whether BC patient-derived xenograft (PDX)-bearingmice could provide a constant and renewable source of
CTCs and BM-DTCs as a unique system to study the mo-
lecular changes responsible for tumor progression and me-
tastases. Here, we report the detection of human CTCs
and BM-DTCs in various BC PDX mice models [26]. To
identify the PDX lines with high numbers of CTCs and
BM-DTCs, we screened a total of 18 lines representing dif-
ferent molecular subclasses of BC. Further, we evaluated
the association of CTC detection with the presence of BM-
DTCs and with the lung metastatic potential of these PDX
lines. Finally, we determined the predictive value of a gen-
etic profile computed from the primary tumors of various
PDX lines that was associated with the presence of CTC
clusters and lung metastatic potential.
Methods
BC PDX mouse models
BC PDX mouse models were established in Dr. Michael
Lewis’ laboratory at the Lester and Sue Smith Breast
Center in Baylor College of Medicine. Methods used to
establish these PDX models have been recently reported
[26]. Mice transplanted with tumors from passages 2
through 11 were used for our studies. Animal care for
the mice bearing the BC PDX tumors, as well as age-
and gender-matched control mice, was in accordance
with the NIH Guide for the Care and Use of Experimen-
tal Animals with approval from the Baylor College of Medi-
cine Institutional Animal Care and Use Committee.
In brief, mammary fat pad epithelium was surgically
cleared from 3- to 4-week-old SCID/Beige female mice.
Subsequently, fresh breast tumor fragments collected
directly from patients were orthotopically transplanted
into the cleared mammary fat pads. When tumor size
reached 1,000 mm3, mice were killed, and tumors were
re-transplanted into additional mice up to 11 passages.
Importantly, the primary and serially passaged PDXs
have shown genomic, proteomic, phenotypic, and histo-
logic consistency with the tumor of origin, and they are
also genetically and proteomically stable across multiple
transplant generations [26].
Detection of CTCs, BM-DTCs, and lung metastases
After anesthesia, peripheral blood (500 to 700 μl) was col-
lected from the vena cava inferior of each animal, which
was then killed by cervical dislocation. Tibias, femurs, and
hip-bones were collected, and bone marrow was flushed
from the bones by using phosphate-buffered saline (PBS)
supplemented with 2 mM ethylenediaminetetraacetic acid
(EDTA). Whole blood was processed within 1 hour of col-
lection to lyse red blood cells (RBCs) by incubation with
ammonium chloride (StemCell Technologies, Vancouver,
BC, Canada) per manufacturer’s protocol.
RBC-depleted cells and bone marrow cells were then
washed twice with PBS at room temperature, pelleted,
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at room temperature. Cell pellets were embedded in par-
affin and cut in consecutive sections of 5-μm thickness.
Five consecutive sections of every 15 sections were
stained by using immunohistochemistry (IHC) with anti-
human pan-cytokeratin (clone AE1/AE3 against cytoker-
atins 1–8, 10, 13–16, and 19; Source: Dako, Carpinteria,
CA, USA) and nuclear counterstain (hematoxylin). CTCs
and BM-DTCs were identified as cytoplasmic human pan-
cytokeratin-positive and nuclear counterstain-positive cells.
A CTC or BM-DTC cluster was defined as a group of two
or more CTCs or BM-DTCs, respectively. At least two
PDX-bearing mice were tested per line (range, 2 to 7), and
in total, five age-matched non-tumor-bearing female mice
were used as controls. Lung metastases (LMs) were identi-
fied by IHC in these PDX lines and were reported in the
previous study [26].
Genetic signature of primary tumors associated with CTC
clusters and LM
The following nine of 18 screened lines had published
Affymetrix gene expression data (GEO:GSE46106), and
at least three mice screened for CTCs (BCM-3107,
BCM-3204, BCM-3561, BCM-3613, BCM-3887, BCM-
3963, BCM-4272, BCM-4664, BCM-4888) [26]. Of these
nine lines, CTC clusters were present in three lines and
LM were detected in six lines (Table 1). To identifyTable 1 Identification of CTCs and BM-DTCs in BC PDX lines a
PDX line CTC detection
rate (%)
Number of CTCs per 20 K nucleated
cells (≈20 μl of blood)
BCM-3107* 1/4 (25) 7
BCM-3143 0/2 (0) 0
BCM-3204* 2/4 (50)Cl 3-43
BCM-3561* 2/4 (50) 1
BCM-3613* 1/3 (33) 7
BCM-3807 0/4 (0) 0
BCM-3887* 3/4 (75)Cl 3-92
BCM-3963* 1/6 (17) 7
BCM-4195 0/2 (0) 0
BCM-4272* 3/3 (100) <1-25
BCM-4664* 1/3 (33) 2
BCM-4888* 5/5 (100)Cl 3-28
BCM-5097 3/6 (50)Cl 10-91
BCM-5156 3/5 (60) 1-28
BCM-5438 2/2 (100) 2-3
BCM-5471 3/6 (50)Cl 1-10
BCM-5998 5/7 (71) <1-27
BCM-6257 3/3 (100)Cl 3-4
BC, breast cancer; BM, bone marrow; BM-DTCs, disseminated tumor cells in bone m
PDX, patient-derived xenograft. Cl represents presence of CTCs and BM-DTCs in clusdifferential genetic signatures corresponding to CTC
clusters and to LM, analysis of variance followed by t-
tests were performed by applying linear modeling to our
microarray experiments by using the Linear Models for
Microarray Data (LIMMA) method, and subsequent man-
ual curation was used, as described previously [27]. A gen-
etic profile overlapping these two genetic signatures
was derived and interrogated for prediction of distant
metastasis-free survival in publicly available datasets [28].
Statistics
The number of CTCs was reported per 20,000 nucleated
cells (≈20 μl of blood). This was based on our initial test-
ing of >20 representative mice from nine PDX models
showing that the average number of RBC-depleted nucle-
ated cells was 20,000 per 20 μl of blood collected. The
DTC count was reported as number of DTCs per 2 mil-
lion bone marrow cells. In addition, the CTC and BM-
DTC detection rates were calculated per each PDX line as
the ratio of the number of mice with one or more CTCs
and DTCs, respectively, and the number of mice tested.
Lung metastatic rate was previously reported as the ratio
of the mice affected by metastases and the number of mice
tested per each line [26]. The association between the
presence of CTCs and BM-DTCs was evaluated within
the same mice by using Fisher’s Exact test and Cochran-
Mantel-Haenszel test to adjust for different PDX lines.nd previously reported presence of LM
BM-DTC detection
rate (%)
Number of BM-DTCs per
2 × 106 BM cells
LM rate [26] (%)
1/2 (50) 1 0
0/2 (0) 0 0
0/2 (0) 0 29
ND ND 0
0/2 (0) 0 24
1/2 (50) 29 0
1/5 (20) <1 14
0/4 (0) 0 14
0/2 (0) 0 0
4/6 (67)Cl <1-132 29
ND ND 0
0/4 (0) 0 67
3/5 (60) 12-30 36
1/2 (50) 2 0
2/2 (100) 4-67 0
2/4 (50)Cl <1-6 33
6/8 (75)Cl 1-40 0
2/3 (67)Cl 22-39 6
arrow; CTC,s circulating tumor cells, LM, lung metastasis, ND, not determined,
ters. * indicates the lines with published Affymetrix data.
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table without different strata representing different PDX
lines. The association between the ability to produce CTCs
or CTC cluster occurrence and the presence of LM was
assessed within each line because the latter was evaluated
in a previous study [26]. These associations were assessed
by Fisher’s Exact test, and data were represented in 2 × 2
contingency table. To derive genetic signatures associated
with CTC clusters and LM, genes that were differentially
expressed and had some statistical evidence of being re-
peatable were considered; this signature was determined
by using a linear contrast t test q–value (also called
false discovery rate (FDR)) <0.25 or at least 16-fold
average difference in expression between LM-positive
and LM-negative PDX lines, which corresponds to a
log2 contrast between LM-positive and LM-negative
scoring greater than 4 in absolute value. To determine
the prognostic value of the four-gene profile, gene-
expression data of human BC [28] were each scored, taking
the sum of the two “upregulated” genes minus the sum of
the two “downregulated” genes (by using z-normalized ex-
pression values). All P values reported were two-sided, un-
less otherwise specified.
Results
BC PDX line characteristics
We used 18 PDX-bearing mouse models, which have
been described in detail previously [26]. Sixteen of these
lines (89%) were established by using primary breast
tumor fragments obtained from patients without metas-
tases. The other two lines (BCM-3561 and BCM-3613)
were developed by transplanting tumor cells isolated
from ascites and pleural fluid collected from two pa-
tients with metastatic disease, respectively. Among the
lines we screened, one line (BCM-5097) was estrogen
receptor (ER)-positive, progesterone receptor (PR)-
positive, but human epidermal growth factor receptor
2 (HER2) negative; three lines were ER-negative and PR-
negative, but HER2-positive (BCM-3143, BCM-3613,
BCM-3963); one line was positive for ER, PR, and HER2
(BCM-4888); the remaining 13 lines (72%) were triple
(ER, PR, HER2)-negative. All the tumor transplants were
positive for either CK19 or CK5/6 or both, as previously
reported [26].
Detection of CTCs, BM-DTCs, and LM in BC PDX lines
All five age-matched control female mice were negative
for both CTCs and BM-DTCs. Individual CTC and BM-
DTC detection data in all tested mice are reported in
Additional file 1: Table S1. Of 81 mice, only eight did
not have adequate sample for CTC analysis and are
labeled as NA (not available). The DTC analysis was ini-
tiated later when we already had collected CTC data
for >20 mice. Therefore, DTC data were not availablefor a total of 28 mice because of either inadequate or no
bone marrow sample.
Among the 18 PDX lines screened, we detected CTCs
in 15 (83%) (Table 1). The rate of CTC detection, de-
fined as number of mice positive for CTCs divided by
total number of mice tested, for CTC-positive PDX lines
ranged from 17% to 100%. CTCs were identified either
as individual cells or as clusters of cells that were pan-
cytokeratin positive (Figure 1). We found CTC clusters
in six of the 18 PDX lines (33%) (Table 1); of these, four
were triple-negative (BCM-3204, BCM-3887, BCM-5471,
BCM-6257), one was ER/PR/HER2-positive (BCM-4888),
and one was ER/PR-positive and HER2-negative (BCM-
5097). The maximum number of CTCs detected in a single
mouse was 92 per 20 μl of blood, whereas a maximum of
20 to 25 cells was found within a CTC cluster.
BM-DTCs were found in 10 of the 16 PDX lines exam-
ined (62.5%). The rate of BM-DTC detection ranged from
20% to 100% in the BM-DTC-positive lines (Table 1). Simi-
lar to CTCs, BM-DTCs were identified as individual cells
or as clusters (Figure 1). We found that four of 16 (25%)
lines had the presence of BM-DTC clusters (Table 1). Two
lines (BCM-5471 and BCM-6257) had both CTC and BM-
DTC clusters. The highest number of BM-DTCs detected
in the bone marrow of a single mouse was 132 per 2 mil-
lion cells.
LMs, as previously reported [26], were detected in
50% (nine of 18) of PDX lines (Table 1); the detection
rate in the LM-positive lines ranged from 6% to 67%.
Correlation between the presence of CTCs and BM-DTCs
and LM
In total, 81 mice were screened in this study (see Additional
file 1: Table S1). Of these, 46 mice had both CTCs and BM-
DTCs evaluated. The presence of CTCs was strongly asso-
ciated with the presence of BM-DTCs (P = 0.0047, Fisher’s
Exact test, Table 2). Even when the data were adjusted for
PDX line by using the Cochran-Mantel-Haenszel test, the
association was still significant (P = 0.0364).
The LM detection rates in these PDX lines were avail-
able from the previously conducted studies and hence
were evaluated per PDX line rather than per individual
mouse [26]. Remarkably, of the nine PDX lines positive
for LM, all had detectable CTCs. Conversely, CTCs were
detected in only six of the nine lines without LM. Over-
all, among the 13 PDX lines that had detectable CTCs
and had both BM-DTCs and LM rates available, all the
lines had either BM-DTCs or LM or both (Table 1). In
turn, of the 14 lines with BM-DTCs and/or LM, only
one did not have detectable CTCs. Despite this high
concordance, the presence of CTCs in the 18 PDX lines
we screened did not significantly correlate with the oc-
currence of LM previously reported in the same lines
[26] (P = 0.46, Fisher’s Exact test). Interestingly however,
Figure 1 Representative images of CTCs and BM-DTCs. Representative IHC images of pan-cytokeratin–positive CTCs and BM-DTCs isolated
from mouse peripheral blood and BM, respectively. Left: Representative images of a CTC (upper panel) and a BM-DTC (lower panel) detected as
isolated (single) cells. Right: Representative images of CTC clusters (upper panel) and BM-DTC clusters (lower panel).
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lung metastatic potential (P = 0.009, Fisher’s Exact test,
Table 3). All six lines in which CTC clusters were found
also had developed LM (Table 1). When the analysis was
restricted to the 13 lines with triple negative BC PDX,
this association was also significant (P = 0.007, Fisher’s
Exact test).
Genetic signature of primary tumor associated with CTCs
clusters and LM
Because of the association between the presence of CTC
clusters and LM, we wanted to understand the genetic
signatures of the primary PDX tumors that give rise to
CTC clusters and LM. We computed two separate gen-
etic signatures associated with the presence of CTC clus-
ters and with lung metastatic potential by using the
gene-expression arrays of primary tumors from different
PDX lines. We identified a set of 35 genes, which formed
the CTC cluster-associated signature (see Additional file 2:
Table S2). The LM-associated gene signature included 34
genes (Additional file 2: Table S3). Overlapping these twoTable 2 Correlation between the presence of CTCs and





Number of mice with CTCs 16 13
Number of mice without CTCs 2 15
The data are presented in the 2 × 2 collapsed table, ignoring the strata
representing different PDX lines. P = 0.0047; Fisher’s Exact test and P = 0.0364;
Cochran-Mantel-Haenszel test, adjusting for PDX line.
BC, breast cancer; BM-DTC, disseminated tumor cells in bone marrow;
CTC, circulating tumor cell; PDX, patient-derived xenograft.gene signatures resulted in a four-gene profile (Table 4),
which was associated with a modest but significant reduc-
tion in distant metastases-free survival in a large compen-
dium of publicly available datasets of early BC patients
(log-rank P = 0.048, 10-year survival probability of 67% for
patients in the top 33% of signature scores versus 73% for
the rest of the patients) (Figure 2). This gene profile in-
cluded two genes (HLA-DP1A and GJA1) that were down-
regulated and two genes (PEG3 and XIST) that were
upregulated (Table 4).
Discussion
Multiple lines of evidence suggest that CTCs and BM-
DTCs can be used to study the metastatic process and
be evaluated in “real-time” to monitor the molecular
changes in progressing tumors. However, their use has
been largely limited because of challenges in their isola-
tion as well as the very low yield of cells detected in hu-
man subjects, especially in the early stages of disease. As
an alternative strategy, we established the conditions for
the detection of human CTCs and BM-DTCs in unique
BC PDX models in this study. As previously shown,
these preclinical models accurately resemble theirTable 3 Correlation between the presence of CTC clusters





Number of lines with CTC clusters 6 0
Number of lines without CTC clusters 3 9
P = 0.009; Fisher’s Exact test.
BC, breast cancer; CTC, circulating tumor cell; LM, lung metastases; PDX,
patient-derived xenograft.
Table 4 Gene profile of BC PDX primary tumors associated
with CTC clusters and LM
Genes Average fold change in
lines with CTC clusters
versus no CTC clusters
Average fold change






*Downregulated genes; ^Upregulated genes.
BC, breast cancer; CTC, circulating tumor cell; LM, lung metastasis; PDX,
patient-derived xenograft.
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biologic behavior [26]. Important in this study, we have
found that BC PDX models can provide a continuous
and renewable source of human CTCs and BM-DTCs.
In support of our findings in BC, a recently published
study showed that CTCs isolated from pancreatic adeno-
carcinoma PDX-bearing mice also represent a reliable
tool to predict and monitor treatment response [29].
The rate of CTC and DTC detection (83% and 62.5%,
respectively) in our studies with PDX models is higher
than that reported in the literature for non-metastatic
breast cancer patients. We attribute this to the differ-
ences in the CTC/DTC detection methods as well as
evaluation of larger blood and bone marrow volume
relative to the body size of PDX mice than that of pa-
tients, as elaborated here. First, most of the commercialFigure 2 Prognostic value of the four-gene profile of BC PDXs
associated with CTC clusters and LM. Four genes were found to
overlap between two genetic signatures of primary tumor associated
with CTC clusters and with lung metastases (LMs). Gene-expression
profiles of human BCs were each scored for this signature (the score
representing the values of the “high” genes minus the values of the
“low” genes). Kaplan-Meier curves compare distant metastasis-free
survival in BC patients with relatively higher signature scoring versus
those with lower scoring. Univariate Cox evaluates the gene-signature
score as a continuous variable. Patient data were extracted from publicly
available datasets [28].techniques to detect CTCs have relied on the presence of
a limited number of epithelial markers (that is, epithelial
cell adhesion molecule (EpCAM) and/or “epithelial” cyto-
keratins 8, 18, 19) [30]. This approach likely omits CTCs
with a predominant mesenchymal phenotype and a lack of
the epithelial markers [25,31-33]. In our approach for
CTC/DTC detection, we used a quantitative immunohis-
tochemistry assay to examine “human” tumor cells for the
expression of multiple cytokeratin subtypes. Indeed, the
pan-cytokeratin antibodies (AE1/AE3) we used bind to
multiple cytokeratins present on both human epithelial
and mesenchymal cells [34,35]. Second, the higher CTC/
DTC detection rate may also result from accessibility to
large amounts of peripheral blood and bone marrow, rela-
tive to the small size of the mouse body. This is in contrast
with only small blood and bone marrow volume used to
assess CTC and DTCs in patients. These factors, as well
as the immunodeficiency status of the PDX models, may
contribute to the higher CTC/DTC detection rates we find
in PDX models. In future, it will be of interest to compare
CTCs/DTCs from patients side-by-side with those de-
rived from matched PDXs as well as to compare charac-
teristics of CTCs/DTCs within various immunodeficiency
models and versus those with reconstituted immune com-
ponents [36].
The observation of clusters of CTCs and BM-DTCs in
the BC PDX-bearing mice is of great interest and further
justifies the use of our PDX lines as clinically representa-
tive models to study these cells. Several studies have
identified multicellular CTC clusters in BC [37,38] and
other types of cancer patients [39-43]. In a recent study,
CTC clusters were found in 26% of patients with small
cell lung cancer, and their presence was an independent
prognostic factor [39]. Moreover, CTC clusters isolated
from BC patients had high expression of mesenchymal
markers and relatively low expression of epithelial
markers, suggesting a potential link between the gener-
ation of CTC clusters and the EMT process [33]. How-
ever, the role of CTC clusters in cancer metastatic
dissemination remains unclear. In our study, we found a
significant association between the presence of CTC
clusters and lung metastatic potential. Only one other
study, to our knowledge, has shown a similar association
in patients with clear cell renal cell carcinoma [41]. The
infrequent finding of clusters of CTCs and BM-DTCs in
other studies may be related to the isolation and detec-
tion techniques. It is possible that our method of pro-
cessing the blood and bone marrow fractions may
facilitate the detection of clusters.
Of note, we found variability in the detection of CTCs
and BM-DTCs in different mice within the same PDX
line. The same variability was also present in the previ-
ously reported LM detection among these lines [26].
This variability may be attributed to the intratumoral
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host-specific factors that may influence tumor initiation
and progression. However, this observation emphasizes
that the future studies to understand the influence of
CTCs in distant metastases should include the analysis
at a mouse level as well as an overall analysis for the
PDX line. In addition, our finding of a significant correl-
ation between the presence of CTCs and BM-DTCs
within the same mice is consistent with what is observed
in early BC patients [17]. All the BC PDX lines that had
CTCs also had BM-DTCs and/or LM. This high con-
cordance rate suggests that these CTCs and BM-DTCs
are early indicators of metastatic potential and as such
are important for molecular characterization and tumor
biology studies. Because BM-DTCs were not evaluated
in sufficient numbers of mice for most lines, correlation
analyses as well as gene-expression analyses in the PDX
lines were restricted to only the CTCs and LM data in
this study. Future studies to characterize molecular pro-
files of CTCs, BM-DTCs, and lung lesions may uncover
important biomarkers and treatment targets to prevent
metastases.
The four-gene profile we obtained by overlapping the
two genetic signatures of primary PDX tumors associ-
ated with CTC clusters and with LM was associated with
a significant reduction in distant metastases-free survival
in early BC patients. However, the observed association
was weak because of limitations such as sample size and
confounding variables, such as different subtypes and
various treatments. Future studies using additional PDX
lines are also necessary to validate this gene profile. In
support of the derived gene profile, however, other re-
ports have independently identified some of these genes
to be associated with LM in BC. For example, HLA-
DP1A, which encodes a transmembrane protein involved
in the antigen-presentation process, was downregulated
in both the CTC clusters and LM signatures. Interest-
ingly, HLA-DP1A was one of the genes downregulated
in the LM signatures generated in two independent
studies in BC [44]. The other downregulated gene in our
four-gene set was GJA1, which encodes a major protein
in gap junctions. GJA1, also known as connexin 43
(Cx43), has been shown to suppress mammary tumor
metastasis to the lung in a mouse model [45]. Specific-
ally, missense mutation (G60S) in this gene led to pro-
duction of an altered Cx43 protein that acts in a
dominant-negative fashion to disrupt gap-junction as-
sembly and function. This mutation was associated with
higher rates of LM in ErbB2-overexpressing mice. Of the
two upregulated genes in our four-gene profile, XIST is
a noncoding RNA gene on X chromosome and plays a
major role in X inactivation. Although overexpression of
XIST has been seen in BRCA-1-associated BCs, which
typically metastasizes to lungs [46,47], a direct linkbetween XIST and LM in BC has not been established.
The other upregulated gene, PEG3, encodes a C2H2 type
zinc finger protein implicated in regulation of body
temperature, feeding behavior, and obesity [48], as well
as growth, apoptosis, and maternal nurturing behavior
[49]. The role of PEG3 in BC and LM is not clear and
warrants further investigation.
Conclusion
The analysis of CTCs and BM-DTCs in the clinical set-
ting is challenging and imposes multiple limitations. In
this study, we provide the first evidence that BC PDX
models represent a novel and promising experimental
resource for investigating the role of CTCs and BM-
DTCs in promoting overt metastases in BC and for their
characterization to identify new treatment targets.
Additional files
Additional file 1: Table S1. Individual mouse data for CTCs and
BM-DTCs for all PDX lines screened.
Additional file 2: Tables S2 and S3. S2. Gene signature of BC PDX
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